tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Zealand Pharma initiated with an Overweight at Wells Fargo

Wells Fargo analyst Cerena Chen initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 650 price target The firm says Zealand is poised to become a key obesity player with petrelintide and survodutide, differentiated assets in emerging amylin and GLP-1/glucagon drug classes. The first half of 2026 readouts for both in obesity should unlock potential for greater than $4B combined peak revenue opportunity, Wells adds.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1